<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00414349</url>
  </required_header>
  <id_info>
    <org_study_id>796838</org_study_id>
    <nct_id>NCT00414349</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Topical Versus Systemic Treatment in Postherpetic Neuralgia and Diabetic Polyneuropathic Pain</brief_title>
  <official_title>Safety and Efficacy of Lidocaine 5% Medicated Plaster in Comparison to Systemic Treatment in Postherpetic Neuralgia and Diabetic Polyneuropathic Pain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grünenthal GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grünenthal GmbH</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate lidocaine as topical treatment for peripheral
      neuropathic pain (as stand-alone treatment and in combination with systemic treatment)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of pain expressed by response rate after 4 weeks treatment every 4 weeks of single or combination treatment: change in neuropathic pain, change in quality of life, change in sleep quality</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical analgesic</intervention_name>
    <description>max. 3 plasters per day for PHN patients max. 4 plasters per day for DPN patients</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral intake</intervention_name>
    <description>300 to 600 mg per day taken orally</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical analgesic</intervention_name>
    <description>3 plasters for PHN patients per day 4 plasters for DPN patients per day</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects with &gt;= 18 years of age

          -  Intact skin in the area of topical treatment

          -  Creatinine clearance CLCR &gt;= 30 mL/min

          -  NRS-3 &gt; 4 (recalled average pain intensity during the last 3 days)

        Subjects with DPN

          -  Controlled, treated type 1 or 2 diabetes mellitus with glycosylated hemoglobin
             (Hba1c)&lt;= 11%

          -  Painful, distal symmetrical, sensomotor polyneuropathy of the lower extremities for &gt;=
             3 months (below the knees on both extremities) with at least 2 of the following
             symptoms present: burning, sensation, tingling or prickling, numbness from time to
             time, painful heat or cold sensation (e.g. warm or cold water)

        Subjects with PHN

          -  Subjects with PHN and neuropathic pain present for &gt;= 3 months after healing of the
             herpes zoster skin rash.

          -  Without neurolytic neurosurgical therapy for their condition.

        Exclusion Criteria:

        General

          -  Evidence or history of alcohol, medication or drug abuse and/or dependency in the past
             2 years, unstable psychological personality requiring intermittent or permanent
             treatment.

          -  Psychiatric illness (subjects with well-controlled depression or anxiety disorder may
             participate if they are not taking any of the prohibited medications defined (below),
             epilepsy or suicide risk.

          -  Pregnant or breastfeeding women

          -  Women of childbearing potential who are sexually active without satisfactory
             contraception for at least 28 days prior to enrollment, during the trial, and until 28
             days after the follow-up visit.

          -  Subjects with severe cardiac impairment e.g. NYHA class &gt; 3, myocardial infarction
             less than 6 months prior to enrollment, and/or unstable angina pectoris.

          -  Subjects with severe hepatic disorder and/or AST or ALT &gt;= 3x the upper limit of
             normal.

          -  Subjects with known or suspected severe renal failure (CLCR &lt; 30 mL/min).

          -  Anticipated need for surgery during the trial, requiring at least regional or general
             anesthesia.

          -  Subjects who are undergoing active treatment for cancer, are known to be infected with
             HIV or being acutely and intensively immunosuppressed following transplantation.

          -  Participation in another trial of investigational medicinal products or devices
             parallel to or less than 1 month before entry into the trial, or previous
             participation in this trial.

        Trial specific:

          -  Any concomitant use of drugs for the treatment of neuropathic pain or commonly used
             for the treatment of neuropathic pain.

          -  Use of transcutaneous electrical nerve stimulations (TENS) after enrollment.

          -  CLCR &lt; 30 mL/min

          -  Evidence of another cause for pain in the area of neuropathic pain such as lumbar
             radiculopathy, surgery trauma, restless legs syndrome, if this coud confound the
             assessment or self-evaluation of the neuropathic pain.

          -  Presence of other severe pain that could confound the assessment or self-evaluation of
             the neuropathic pain.

          -  History of malignancy within the past 5 years (with the exception of basal cell
             carcinoma).

        Subjects with PHN

          -  Active herpes zoster lesion or dermatitis of any origin at the affected site with PHN.

          -  Subjects who had neurological ablation by block or neurosurgical intervention for
             control of pain in PHN.

        Subjects with DPN

          -  No palpable pulse of the arteria dorsalis pedis in both feet.

          -  Clinical signs for venous insufficiency and/or postthrombotic syndrome Sage III/IV
             (i.e. extensive varicoses)

          -  Ulcers on the lower extremities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralf Baron, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Neurologie, Christian-Albrechts-Universität Kiel, Schittenhelmstr. 10, 24105 Kiel, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin. 2009 Jul;25(7):1663-76. doi: 10.1185/03007990903047880.</citation>
    <PMID>19485723</PMID>
  </results_reference>
  <results_reference>
    <citation>Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. Curr Med Res Opin. 2009 Jul;25(7):1677-87. doi: 10.1185/03007990903048078.</citation>
    <PMID>19480610</PMID>
  </results_reference>
  <results_reference>
    <citation>Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled trial. Clin Drug Investig. 2009;29(4):231-41. doi: 10.2165/00044011-200929040-00002.</citation>
    <PMID>19301937</PMID>
  </results_reference>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2006</study_first_submitted>
  <study_first_submitted_qc>December 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2006</study_first_posted>
  <last_update_submitted>June 15, 2009</last_update_submitted>
  <last_update_submitted_qc>June 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Grünenthal GmbH</name_title>
    <organization>Grünenthal GmbH</organization>
  </responsible_party>
  <keyword>Topical analgesic</keyword>
  <keyword>Multiple dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

